TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.
Bosma AL, Spuls PI, Garcia-Doval I, Naldi L, Prieto-Merino D, Tesch F, Apfelbacher CJ, Arents BWM, Barbarot S, Baselga E, Deleuran M, Eichenfield LF, Gerbens LAA, Irvine AD, Manca A, Mendes-Bastos P, Middelkamp-Hup MA, Roberts A, Seneschal J, Svensson Å, Thyssen JP, Torres T, Vermeulen FM, Vestergaard C, von Kobyletzki LB, Wall D, Weidinger S, Schmitt J, Flohr C.
Bosma AL, et al. Among authors: vermeulen fm.
Br J Dermatol. 2020 Jun;182(6):1423-1429. doi: 10.1111/bjd.18452. Epub 2019 Nov 20.
Br J Dermatol. 2020.
PMID: 31444799
BACKGROUND: A long-term prospective observational safety study is essential to characterize fully the safety profile of systemic immunomodulating therapies for patients with atopic eczema. ...What's already known about this topic? There is a need for long-term data …
BACKGROUND: A long-term prospective observational safety study is essential to characterize fully the safety profile of systemic immu …